Mahamaya Lifesciences FY26 Revenue ₹328.87 Cr, PAT ₹16.52 Cr

Mahamaya Lifesciences Ltd has released its Annual Report for the Financial Year 2025-26. The report highlights significant growth, with Revenue from Operations reaching ₹328.87 crore, a 24.5% year-on-year increase. EBITDA grew by 32.6% YoY to ₹34.26 crore, resulting in an improved EBITDA margin of 10.42% compared to 9.78% in FY25. Profit After Tax (PAT) saw a substantial increase of 29.0% YoY to ₹16.52 crore, with Basic EPS at ₹8.33. The company also improved its financial leverage, with Net Debt/Equity ratio decreasing to 0.74x from 1.18x in the previous fiscal year. The report details the company's strategic focus on manufacturing excellence, R&D, global presence, and sustainable agricultural solutions, aiming to become a leading innovation-driven agricultural sciences company.